Total Body PET plays a significant role in oncology research and clinical applications, offering comprehensive, dynamic imaging of cancer throughout the body. This technology provides precise insights into tumour metabolism, heterogeneity, and treatment response, assisting in early detection, therapy monitoring, and recurrence assessment. Its contribution to advancing personalised medicine and enhancing patient outcomes highlights its importance in modern oncology practice.

Join us for our upcoming webinar to explore the role total body PET may play in clinical research and drug development for oncology, and delve into the potential of dynamic, multi-parametric total-body PET imaging in advancing oncological practices.

In this webinar:

· Professor Andrew Scott, Olivia Newton-John Cancer Research Institute, will delve into the application of total body PET in clinical research, shedding light on its implications for drug development in the field of oncology.

· Associate Professor Nikolaos Karakatsanis, Cornell University, will discuss the utilisation of dynamic, multi-parametric total body PET imaging, exploring its potential avenues within the realm of oncology research.

· The presentations will be followed by a short Q&A session.

**If you missed any of the previous webinars you can find the recordings here.

About the Facility:

Imaging to understand whole-body processes such as novel drug interactions during therapeutic development is now accessible through Australia’s first open-access research-dedicated Total Body PET (TB-PET).

The Sydney Imaging Core Research Facility at The University of Sydney, in partnership with Northern Sydney Local Health District (NSLHD) and the National Imaging Facility (NIF), launched the Australian National Total Body PET Facility in the Department of Nuclear Medicine at Royal North Shore Hospital.

TB-PET can be used to capture molecular processes from all organs simultaneously. The high-performance instrument can be used to study diseases that affect the entire body and build a better picture of complex processes such as ageing, metabolism, brain signalling and drug interactions.

Due to its exquisite sensitivity, it also has the potential to use much lower radiation doses compared to conventional PET scanners, making it safer to scan children, healthy volunteers, and to scan patients repeatedly to better understand disease progression and treatment effects.

TB-PET is accessible for research studies through Sydney Imaging Core Research Facility, the University of Sydney Node of the National Imaging Facility. For more information, contact Dr Georgios Angelis.